Prevalence of the limited vs. extensive scleroderma-related interstitial lung disease at the time of diagnosis of SSc-ILD based on Goh et al. criteria. Systematic review and meta-analysis

Manuel Rubio-Rivas , Melani Pestaña-Fernández
{"title":"Prevalence of the limited vs. extensive scleroderma-related interstitial lung disease at the time of diagnosis of SSc-ILD based on Goh et al. criteria. Systematic review and meta-analysis","authors":"Manuel Rubio-Rivas ,&nbsp;Melani Pestaña-Fernández","doi":"10.1016/j.rceng.2024.02.008","DOIUrl":null,"url":null,"abstract":"<div><h3>Introduction</h3><p>Goh et al. proposed in 2008 a classificatory algorithm of limited or extensive SSc-ILD. The prevalence of both at the time of diagnosis of SSc-ILD is not known with exactitude.</p></div><div><h3>Methods</h3><p>The review was undertaken by means of MEDLINE and SCOPUS from 2008 to 2023 and using the terms: \"systemic\", \"scleroderma\" or \"interstitial lung disease\" [MesH]. The Newcastle-Ottawa Scale was used for the qualifying assessment for observational studies and the Jadad scale for clinical trials. The inverse variance-weighted method was performed.</p></div><div><h3>Results</h3><p>Twenty-seven studies were initially included in the systematic review and meta-analysis (SRMA). Of these, 17 studies had no overlapping data. They reported data from 2,149 patients, 1,369 (81.2%) were female. The mean age was 52.4 (SD 6.6) years. 45.2% of the patients had the diffuse subtype and 54.8% had the limited or sine scleroderma subtype. A total of 38.7% of the patients showed positive antitopoisomerase antibodies (ATA) and 14.2% positive anticentromere antibodies (ACA). The mean percentage of forced vital capacity (FVC) at baseline was 80.5% (SD 6.9) and of diffusing capacity of the lungs for carbon monoxide (DLco) was 59.1% (SD 9.6). Twelve studies presented SSc-ILD extension data adjusted for PFTs and were included in the meta-analysis. The 10 observational cohort studies were analyzed separately. The overall percentage of limited extension was estimated at 63.5% (95%CI 55.3–73; p &lt; 0.001) using the random-effects model. Heterogeneity between studies (I<sup>2</sup>) was 9.8% (95%CI 0–68.2%) with the random-effects model. Extensive pulmonary involvement was estimated at 34.3% (95%CI 26–45.4; p &lt; 0.001). Heterogeneity between studies (I<sup>2</sup>) was 0% (95%CI 0–61.6%) with the random-effects model.</p></div><div><h3>Conclusion</h3><p>The overall percentage of limited SSc-ILD at the time of diagnosis of SSc-ILD was estimated at 63.5% and extensive at 34.3%.</p></div>","PeriodicalId":94354,"journal":{"name":"Revista clinica espanola","volume":"224 4","pages":"Pages 189-196"},"PeriodicalIF":0.0000,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Revista clinica espanola","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2254887424000316","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Introduction

Goh et al. proposed in 2008 a classificatory algorithm of limited or extensive SSc-ILD. The prevalence of both at the time of diagnosis of SSc-ILD is not known with exactitude.

Methods

The review was undertaken by means of MEDLINE and SCOPUS from 2008 to 2023 and using the terms: "systemic", "scleroderma" or "interstitial lung disease" [MesH]. The Newcastle-Ottawa Scale was used for the qualifying assessment for observational studies and the Jadad scale for clinical trials. The inverse variance-weighted method was performed.

Results

Twenty-seven studies were initially included in the systematic review and meta-analysis (SRMA). Of these, 17 studies had no overlapping data. They reported data from 2,149 patients, 1,369 (81.2%) were female. The mean age was 52.4 (SD 6.6) years. 45.2% of the patients had the diffuse subtype and 54.8% had the limited or sine scleroderma subtype. A total of 38.7% of the patients showed positive antitopoisomerase antibodies (ATA) and 14.2% positive anticentromere antibodies (ACA). The mean percentage of forced vital capacity (FVC) at baseline was 80.5% (SD 6.9) and of diffusing capacity of the lungs for carbon monoxide (DLco) was 59.1% (SD 9.6). Twelve studies presented SSc-ILD extension data adjusted for PFTs and were included in the meta-analysis. The 10 observational cohort studies were analyzed separately. The overall percentage of limited extension was estimated at 63.5% (95%CI 55.3–73; p < 0.001) using the random-effects model. Heterogeneity between studies (I2) was 9.8% (95%CI 0–68.2%) with the random-effects model. Extensive pulmonary involvement was estimated at 34.3% (95%CI 26–45.4; p < 0.001). Heterogeneity between studies (I2) was 0% (95%CI 0–61.6%) with the random-effects model.

Conclusion

The overall percentage of limited SSc-ILD at the time of diagnosis of SSc-ILD was estimated at 63.5% and extensive at 34.3%.

根据 Goh 等人的标准,在诊断 SSc-ILD 时局限性硬皮病与广泛性硬皮病间质性肺病的患病率。系统回顾和荟萃分析。
导言Goh等人于2008年提出了一种局限性或广泛性SSc-ILD的分类算法。目前尚不清楚在确诊 SSc-ILD 时这两种疾病的发病率:方法:通过 2008 年至 2023 年的 MEDLINE 和 SCOPUS 进行回顾,使用的术语包括"系统性"、"硬皮病 "或 "间质性肺病"[MesH]。观察性研究采用纽卡斯尔-渥太华量表(Newcastle-Ottawa Scale)进行合格评估,临床试验采用贾达德量表(Jadad Scale)进行合格评估。研究采用反方差加权法:最初有 27 项研究被纳入系统综述和荟萃分析 (SRMA)。其中,17 项研究的数据没有重叠。这些研究报告了 2,149 名患者的数据,其中 1,369 名患者(81.2%)为女性。平均年龄为 52.4 (SD 6.6)岁。45.2%的患者属于弥漫性亚型,54.8%的患者属于局限性或正弦硬皮病亚型。38.7%的患者抗异构酶抗体(ATA)呈阳性,14.2%的患者抗中心粒抗体(ACA)呈阳性。基线时强迫生命容量(FVC)的平均百分比为 80.5%(SD 6.9),一氧化碳肺弥散容量(DLco)的平均百分比为 59.1%(SD 9.6)。12项研究提供了根据PFTs调整后的SSc-ILD扩展数据,并纳入了荟萃分析。对 10 项观察性队列研究进行了单独分析。在随机效应模型中,局限性扩展的总比例估计为 63.5%(95%CI 55.3-73;P 2),而局限性扩展的总比例估计为 9.8%(95%CI 0-68.2%)。肺部广泛受累的比例估计为 34.3% (95%CI 26-45.4; p 2) ,随机效应模型为 0% (95%CI 0-61.6%) 结论:在诊断为 SSc-ILD 时,局限性 SSc-ILD 的总比例估计为 63.5%,广泛性为 34.3%。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信